Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
TLRY vs CGC vs CRON vs ACB vs SMG
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Agricultural Inputs
TLRY vs CGC vs CRON vs ACB vs SMG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Agricultural Inputs |
| Market Cap | $660M | $122M | $981M | $195M | $3.62B |
| Revenue (TTM) | $1.17B | $294M | $193M | $361M | $3.35B |
| Net Income (TTM) | $-2.95B | $-327M | $-9M | $41M | $90M |
| Gross Margin | 28.0% | 22.8% | 32.5% | 62.7% | 31.0% |
| Operating Margin | -266.0% | -24.1% | -1.5% | 13.3% | 11.7% |
| Forward P/E | — | — | 34.3x | 164.2x | 14.2x |
| Total Debt | $451M | $348M | $2M | $104M | $2.38B |
| Cash & Equiv. | $304M | $114M | $792M | $184M | $37M |
TLRY vs CGC vs CRON vs ACB vs SMG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | 100 | 57.5 | -42.5% |
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
| Cronos Group Inc. (CRON) | 100 | 39.4 | -60.6% |
| Aurora Cannabis Inc. (ACB) | 100 | 2.4 | -97.6% |
| The Scotts Miracle-… (SMG) | 100 | 43.7 | -56.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLRY vs CGC vs CRON vs ACB vs SMG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TLRY is the clearest fit if your priority is momentum.
- +12.1% vs ACB's -25.3%
Among these 5 stocks, CGC doesn't own a clear edge in any measured category.
CRON has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.98
- Rev growth 64.4%, EPS growth -100.0%, 3Y rev CAGR 30.6%
- 14.6% 10Y total return vs TLRY's -74.7%
- Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
ACB is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 11.2% margin vs TLRY's -252.6%
- 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%
SMG ranks third and is worth considering specifically for value and dividends.
- Lower P/E (14.2x vs 164.2x)
- 4.2% yield; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 64.4% revenue growth vs CGC's -9.5% | |
| Value | Lower P/E (14.2x vs 164.2x) | |
| Quality / Margins | 11.2% margin vs TLRY's -252.6% | |
| Stability / Safety | Beta 0.98 vs TLRY's 2.03, lower leverage | |
| Dividends | 4.2% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +12.1% vs ACB's -25.3% | |
| Efficiency (ROA) | 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2% |
TLRY vs CGC vs CRON vs ACB vs SMG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TLRY vs CGC vs CRON vs ACB vs SMG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACB leads in 2 of 6 categories
TLRY leads 2 • CGC leads 0 • CRON leads 0 • SMG leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SMG is the larger business by revenue, generating $3.4B annually — 17.3x CRON's $193M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $294M | $193M | $361M | $3.4B |
| EBITDAEarnings before interest/tax | -$3.0B | -$32M | -$810,000 | $71M | $466M |
| Net IncomeAfter-tax profit | -$2.9B | -$327M | -$9M | $41M | $90M |
| Free Cash FlowCash after capex | -$94M | -$86M | -$163,766 | -$31M | $358M |
| Gross MarginGross profit ÷ Revenue | +28.0% | +22.8% | +32.5% | +62.7% | +31.0% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -24.1% | -1.5% | +13.3% | +11.7% |
| Net MarginNet income ÷ Revenue | -2.5% | -111.0% | -4.9% | +11.2% | +2.7% |
| FCF MarginFCF ÷ Revenue | -8.1% | -29.3% | -0.1% | -8.7% | +10.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.0% | +20.9% | +2.0% | +6.8% | -15.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +70.7% | +83.8% | -100.0% | -94.5% | -78.5% |
Valuation Metrics
TLRY leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 25.3x trailing earnings, SMG trades at a 85% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than SMG's 13.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $660M | $122M | $981M | $195M | $3.6B |
| Enterprise ValueMkt cap + debt − cash | $806M | $293M | $190M | $136M | $6.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -0.28x | — | 164.21x | 25.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 34.27x | — | 14.23x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 6.73x | 13.75x |
| Price / SalesMarket cap ÷ Revenue | 0.59x | 0.62x | 5.07x | 0.77x | 1.06x |
| Price / BookPrice ÷ Book value/share | 0.25x | 0.34x | 0.90x | 0.43x | — |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 13.22x |
Profitability & Efficiency
ACB leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -136.5% | -43.1% | -0.9% | +7.2% | — |
| ROA (TTM)Return on assets | -100.6% | -29.5% | -0.8% | +5.2% | +2.9% |
| ROICReturn on invested capital | -66.2% | -10.2% | -0.8% | +0.7% | +13.3% |
| ROCEReturn on capital employed | -78.1% | -12.4% | -0.3% | +0.7% | +17.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.22x | 0.72x | 0.00x | 0.17x | — |
| Net DebtTotal debt minus cash | $147M | $235M | -$790M | -$80M | $2.3B |
| Cash & Equiv.Liquid assets | $304M | $114M | $792M | $184M | $37M |
| Total DebtShort + long-term debt | $451M | $348M | $2M | $104M | $2.4B |
| Interest CoverageEBIT ÷ Interest expense | -89.43x | -7.79x | — | 6.27x | 3.08x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, TLRY leads with a +1209.3% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs CGC's -55.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -41.8% | -5.0% | -4.8% | -21.0% | +6.1% |
| 1-Year ReturnPast 12 months | +1209.3% | -12.4% | +38.9% | -25.3% | +20.7% |
| 3-Year ReturnCumulative with dividends | +103.6% | -91.4% | +29.1% | -47.2% | -3.2% |
| 5-Year ReturnCumulative with dividends | -65.0% | -99.6% | -66.6% | -96.1% | -69.1% |
| 10-Year ReturnCumulative with dividends | -74.7% | -94.3% | +1457.6% | -92.0% | +34.9% |
| CAGR (3Y)Annualised 3-year return | +26.7% | -55.9% | +8.9% | -19.2% | -1.1% |
Risk & Volatility
Evenly matched — CRON and SMG each lead in 1 of 2 comparable metrics.
Risk & Volatility
CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SMG currently trades 86.2% from its 52-week high vs TLRY's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 1.90x | 0.98x | 1.81x | 1.10x |
| 52-Week HighHighest price in past year | $15.70 | $2.38 | $3.43 | $6.67 | $72.35 |
| 52-Week LowLowest price in past year | $0.35 | $0.84 | $1.84 | $3.07 | $52.00 |
| % of 52W HighCurrent price vs 52-week peak | +36.1% | +47.5% | +74.9% | +51.4% | +86.2% |
| RSI (14)Momentum oscillator 0–100 | 37.9 | 52.9 | 49.3 | 52.2 | 48.9 |
| Avg Volume (50D)Average daily shares traded | 4.7M | 10.4M | 1.4M | 979K | 938K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TLRY as "Hold", CGC as "Hold", CRON as "Hold", ACB as "Hold", SMG as "Buy". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2). SMG is the only dividend payer here at 4.21% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | $10.00 | $14.47 | $2.30 | $5.92 | $72.00 |
| # AnalystsCovering analysts | 20 | 26 | 15 | 14 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +4.2% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.63 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.0% | 0.0% | +0.5% |
ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 2 (Valuation Metrics, Total Returns). 1 tied.
TLRY vs CGC vs CRON vs ACB vs SMG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TLRY or CGC or CRON or ACB or SMG a better buy right now?
For growth investors, Cronos Group Inc.
(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). The Scotts Miracle-Gro Company (SMG) offers the better valuation at 25. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate The Scotts Miracle-Gro Company (SMG) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TLRY or CGC or CRON or ACB or SMG?
On trailing P/E, The Scotts Miracle-Gro Company (SMG) is the cheapest at 25.
3x versus Aurora Cannabis Inc. at 164. 2x. On forward P/E, The Scotts Miracle-Gro Company is actually cheaper at 14. 2x.
03Which is the better long-term investment — TLRY or CGC or CRON or ACB or SMG?
Over the past 5 years, Tilray Brands, Inc.
(TLRY) delivered a total return of -65. 0%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus CGC's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TLRY or CGC or CRON or ACB or SMG?
By beta (market sensitivity over 5 years), Cronos Group Inc.
(CRON) is the lower-risk stock at 0. 98β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 107% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — TLRY or CGC or CRON or ACB or SMG?
By revenue growth (latest reported year), Cronos Group Inc.
(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: The Scotts Miracle-Gro Company grew EPS 504. 9% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TLRY or CGC or CRON or ACB or SMG?
The Scotts Miracle-Gro Company (SMG) is the more profitable company, earning 4.
3% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMG leads at 10. 5% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TLRY or CGC or CRON or ACB or SMG more undervalued right now?
On forward earnings alone, The Scotts Miracle-Gro Company (SMG) trades at 14.
2x forward P/E versus 34. 3x for Cronos Group Inc. — 20. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.
08Which pays a better dividend — TLRY or CGC or CRON or ACB or SMG?
In this comparison, SMG (4.
2% yield) pays a dividend. TLRY, CGC, CRON, ACB do not pay a meaningful dividend and should not be held primarily for income.
09Is TLRY or CGC or CRON or ACB or SMG better for a retirement portfolio?
For long-horizon retirement investors, Cronos Group Inc.
(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TLRY and CGC and CRON and ACB and SMG?
These companies operate in different sectors (TLRY (Healthcare) and CGC (Healthcare) and CRON (Healthcare) and ACB (Healthcare) and SMG (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TLRY is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; ACB is a small-cap high-growth stock; SMG is a small-cap income-oriented stock. SMG pays a dividend while TLRY, CGC, CRON, ACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.